Pharmaceutical formulations

Abstract

The invention relates to the use of calcium stearate to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier. An inhalable solid pharmaceutical formulation comprising (a) an active ingredient substance susceptible to chemical interaction with lactose, (b) a carrier and (c) calcium stearate is also provided together with uses thereof and methods related thereto.

1 .- 10 . (canceled)  
   
   
       11 . An inhalable solid pharmaceutical formulation comprising (a) an active ingredient substance susceptible to chemical interaction with a carrier, (b) a carrier and (c) calcium stearate.  
   
   
       12 . An inhalable solid pharmaceutical formulation as claimed in  claim 11  wherein the carrier is a reducing sugar.  
   
   
       13 . An inhalable solid pharmaceutical formulation as claimed in  claim 23  wherein the active ingredient substance is 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; or a salt, solvate or physiologically acceptable derivative thereof, and the carrier is lactose.  
   
   
       14 . A method of reducing or inhibiting chemical interaction between an active ingredient substance and a carrier susceptible to chemical interaction, which comprises mixing calcium stearate with said active ingredient substance and said carrier.  
   
   
       15 . A method of inhibiting chemical degradation of an active ingredient substance in a formulation comprising a carrier and an active ingredient substance, which method comprises mixing calcium stearate with said active ingredient substance and said carrier.  
   
   
       16 . A method as claimed in  claim 14  further wherein the carrier is a reducing sugar.  
   
   
       17 . (Cancelled).  
   
   
       18 . A method for treating asthma, chronic obstructive pulmonary disease (COPD), chronic or wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, or rhinitis, comprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation as claimed in  claim 11 .  
   
   
       19 . A method of preparing a solid pharmaceutical preparation comprising combining in one or more steps: (a) an active ingredient substance susceptible to interaction with a carrier, (b) a carrier and (c) calcium stearate.  
   
   
       20 . An inhalable solid pharmaceutical formulation as claimed in  claim 12 , wherein the carrier is lactose.  
   
   
       21 . An inhalable solid pharmaceutical formulation as claimed in  claim 11 , wherein the calcium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.  
   
   
       22 . An inhalable solid pharmaceutical formulation as claimed in  claim 11 , wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.  
   
   
       23 . An inhalable solid pharmaceutical formulation as claimed in  claim 11 , wherein said drug substance is selected from: 
 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl) benzenesulfonamide;    3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide;    4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and    4-{(1R)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,    or a salt, solvate or physiologically acceptable derivative thereof.    
   
   
       24 . A method as claimed in  claim 15 , wherein the carrier is lactose.  
   
   
       25 . A method as claimed in  claim 14 , wherein the calcium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.  
   
   
       26 . A method as claimed in  claim 14 , wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.  
   
   
       27 . A method as claimed in  claim 14 , wherein said drug substance is selected from: 
 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide;    3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide;    4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and    4-{(1R)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,    or a salt, solvate or physiologically acceptable derivative thereof.    
   
   
       28 . A method as claimed in  claim 14 , wherein the active ingredient substance is 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl); or a salt, solvate or physiologically acceptable derivative thereof, and the carrier is lactose.